<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We have previously shown a negative correlation between serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels and prevalence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, suggesting that <z:chebi fb="0" ids="16990">bilirubin</z:chebi> inhibits development of this disease </plain></SENT>
<SENT sid="1" pm="."><plain>To confirm this hypothesis, we investigated whether administration of <z:chebi fb="0" ids="17033">biliverdin</z:chebi>, the precursor of <z:chebi fb="0" ids="16990">bilirubin</z:chebi>, protects against the deterioration of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance in db/db mice, a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:chebi fb="0" ids="17033">Biliverdin</z:chebi> (20 mg/kg daily) was orally administered to 5-week-old db/db mice for 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>After 4 weeks of treatment, i.p. <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance and insulin tolerance tests were performed </plain></SENT>
<SENT sid="4" pm="."><plain>Insulin content was evaluated by immunostaining and ELISA </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> markers (8-hydroxy-2'-deoxyguansosine and dihydroethidium staining) and expression of <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase components Pdx1 and Bax were also evaluated in isolated islets </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Treatment with <z:chebi fb="0" ids="17033">biliverdin</z:chebi> partially prevented worsening of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> in db/db mice </plain></SENT>
<SENT sid="7" pm="."><plain>This effect was accompanied by a significant increase in insulin content and Pdx1 expression, and a significant decrease of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and Bax expression in pancreatic islets from db/db mice </plain></SENT>
<SENT sid="8" pm="."><plain>At the same time, levels of <z:mp ids='MP_0003674'>oxidative stress</z:mp> markers and <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase component production in islets were normalised </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="17033">Biliverdin</z:chebi> had little effect on HOMA of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> or <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> evaluated by insulin tolerance tests </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="0" ids="17033">Biliverdin</z:chebi> may protect against progressive worsening of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance in db/db mice, mainly via inhibition of <z:mp ids='MP_0003674'>oxidative stress</z:mp>-induced beta cell damage </plain></SENT>
</text></document>